Introduction {#s0001}
============

Rotavirus (RV) is worldwide recognized as the leading cause of acute gastro-enteritis (AGE) in children \<5 years of age (\<5 yrs). In a recent sentinel surveillance report from 6 regions of World Health Organization (WHO) with different economic levels, about 40% of hospitalizations for diarrhea among children \<5 yrs are attributed to community-acquired RV-infection (CARV). According to the last WHO report, about 450,000 cases of deaths in the world are annually related to CARV, with more than 90% of fatal cases among children. Specifically, more than 300 death per 100,000 cases are estimated in low-income countries of Africa and Asia, and around 1 death per 100,000 in European countries.[@cit0001]

The virus presents an ubiquitous distribution, and a transmission occurring via fecal-oral route with direct or indirect contact through infected person or contaminated fomites, respectively. Child susceptibility to RV infection is the same in both developed and developing countries, with about 95% of children \<5 yrs worldwide having met the virus at least once in their life. The age of first presentation in industrialized countries is around 6--24 months, which is relatively late when compared to developing countries, where the infants are most affected.[@cit0001] RV infection is characterized by a single winter peak in high-income countries with temperate climates and by more than one seasonal peak in low-income countries of Asia and Africa.[@cit0002] RV presents a high transmissibility, due to the large amount of viral particles eliminated in acute phases and a low infective dose (\<100 viral particles). Moreover, it presents a long environmental persistence and a relatively high resistance to disinfectants.[@cit0002] Generally, the first infection is the most severe and presents a more unfavorable outcome in developing countries.[@cit0004]

In the last 2 decades, 3 conditions have deeply increased the differences between developed and developing countries. Specifically, the availability of rehydrating therapy for severe-moderate AGE, the improvement of health conditions and the administration of a RV vaccine have modified RV epidemiology, hospitalization rate and mortality.[@cit0004] Since 2006, a monovalent and a pentavalent live, attenuated oral vaccines are internationally administered.[@cit0002]

Although CARV represents the main manifestation of RV infection, the frequent hospital admission of children \<5 yrs increases the risk of acquiring RV in healthcare departments, especially in emergency department (ED) and pediatric wards.[@cit0003] After its introduction from the community, RV was isolated in 25--55% stool samples of hospitalized children.[@cit0003] Moreover, nosocomial RV (nRV) infection seems to be responsible for around 25% of all RV-related hospitalizations, especially in immunocompromised children.[@cit0002] Nosocomial RV is an important emerging issue; however, the lack of comparable data among studies limits the availability of consistent epidemiological figures for socio-economic evaluation.[@cit0007]

Aim of this review is to summarize the epidemiology of CARV in pre- and post-vaccine era, and divergences about incidence, hospitalization rate and length of nRV in European countries.

Results {#s0002}
=======

CARV: Hospitalization rate and ED visits {#s0002-0001}
----------------------------------------

In Europe, the hospitalization rates for CARV in pre-vaccine era have been counted by the Pediatric ROTavirus European Committee (PROTECT) study.[@cit0011] The authors of this systematic review highlight a median annual incidence rate in children \<5 yrs around 3/1,000 (range 0.3--11.9/1,000), with a higher prevalence (60--80%) for children \<2 years of age; admission for CARV determines a median hospital-stay length of 4.8 days, ranging from 2 to 9.5 d. These data have confirmed through many prospective and retrospective studies.[@cit0012] The most robust results have come from the REVEAL study,[@cit0016] a prospective, multicenter, observational study of pediatric AGE in 7 European countries. According to this study, CARV represents the primary diagnosis of 50% of hospital admissions and ED visits for RV related gastroenteritis, affecting mainly children 6--23 months of age. Furthermore, a difference in the hospitalization rates has been observed, that was related to the different epidemiological features of CARV in both eastern and western countries, and in a different attitude for hospital access of children.[@cit0011] In the post-vaccine era, a reduced burden of CARV was observed in terms of hospitalization rate and ED visits. Giaquinto et al.,[@cit0019] in 2011, observed about 94.5% decrease in hospitalizations and ED visits. Zlamy et al.,[@cit0020] in 2013 in Austria, reported a reduction in hospitalization rate of 74%, and the mean hospital stay for CARV was significantly lower compared to the pre-vaccine era (p \< 0.001), and the overall direct costs reduction was 72.7%.

In those European countries that have adopted RV vaccination, the reduction was observed not only in RV vaccinated age groups. The results of these studies pointed out the possibility of achieving herd immunity, with an overall reduction of incidence and hospitalization rates around 41% and 24% respectively, particularly related to mild cases.[@cit0011]

Nosocomial RV {#s0002-0002}
-------------

An AGE related to RV could be defined as nosocomial every time the symptoms appear from 48 hours after the admission in hospital to 72 hours after hospital discharge.[@cit0021] In particular, some studies have pointed out a 15--30% of cases of nRV after hospital discharge. This amount makes the difference for an additional 0.8--1.0/100 cases in the seasonal incidence in infants and toddlers, although their relevance in increasing direct health care costs is minimal because they are not associated with an increased hospitalization length or a readmission.[@cit0022]

A real nRV estimate is hard to obtain, as the largest studies on nosocomial diseases have focused their attention on adult population. Nonetheless, viruses are the most putative agents for nosocomial disease in pediatric ward (from 23 to 34% of infections). Nosocomial diarrhea is caused by virus in 91--94% of all cases (65--90% of pediatric hospital-acquired infection), with RV responsible for 31--87% of cases.[@cit0023]

We analyzed 23 papers (both original articles and reviews) about nRV,[@cit0011] and we found extreme divergences in incidence and extra length of hospitalization stay estimations. [Table 1](#t0001){ref-type="table"} shows the 23 European studies selected. Table 1.List of selected European studies on nRV.AuthorYear of PublicationStudy designCountryRefGleizes et al.2006ReviewES-FR-GB-IT-PL21PROTECT2006ReviewEU11Johansen et al.2008RSSW22Stefkovicova et al.2008RSSK23Forster et al.2009PSES-DE-FR-GB-IT24Gil-Prieto et al.2009RSES25Muhsen et al.2009PSIL26Waisbourd-Zinman et al.2009PSIL27Wildi-Runge et al.2009RSCH28Cunliffe NA et al.2010PSGB29Festini et al.2010PSIT30Gutiérrez-Gimeno et al.2010PSES31García-Basteiro et al.2011RSES32Panatto et al.2011RSIT33Bruijning-Verhagen et al.2012ReviewWest EU34Ogilvie et al.2012ReviewWest EU18Nitsch-Osuch et al.2013RSPL35Zlamy et al.2013RSAU20Konstantopoulos et al.2013PSGR36Anca et al.2014PSRO37Rinder et al.2014PSSW38Stefcovicova et al.2015PSSK39Redondo-Gonzalez2015RSES40[^2][^3][^4][^5][^6][^7][^8][^9][^10][^11][^12][^13][^14][^15][^16][^17][^18]

Incidence of nRV was calculated in the 23 selected papers, with a sample size from 134 to 355,339, and an age range from 0 to 18 years, with particular focus on the 0--5 y age group. A median of 29 (range 3--277) nRV/1,000 hospitalizations, 198 (30--1030) nRV/100,000 children \<5 yrs, 0.32 (0.03--0.96) nRV/hospitalized CARV, 4.8 (0.46--13) nRV/1,000 d of hospitalization was calculated. [Table 2](#t0002){ref-type="table"} shows 10/23 articles with data from different European countries. Median values from these 10 papers are: 61.5 (range 3--277) for nRV/1,000 hospitalizations; 291.5 (range 160--1030) for nRV/100,000 children \<5 yrs; 0.32 (range 0.03--0.96) for nRV/hospitalized CARV; 5.25 (range 0.52--13) for nRV/1,000 hospitalization-days. In Austria, a comparison of nRV incidence pre- and post-antiRV vaccine introduction showed a significant reduction of the rate nRV/CARV from 11.5% to 3.1%.[@cit0020] Table 2.Incidence of nosocomial RV infection. nRV/1,000 HospitalizationsnRV/100,000 children \< 5 yrsnRV/CARV hospitalizednRV/1,000 d of hospitalizationAge rangeSample sizeRefEurope, 2006 (FR, IT, PL, ES, GB)53---0.618.10--5 y5,47021277---------0--18 m220---1980.64---0--5 y757701600.96130--2 y66633330.76---0--15 y295Israel, 200910------2.40--18 y35,83327United Kindom, 2010------0.63[^\*^](#t2fn0001){ref-type="fn"}---0--16 y57629Spain, 2011---2500.38---0--5 y355,33932Austria, 2013------0.12[^\*^](#t2fn0001){ref-type="fn"}---0--18 y1,02620------0.09[^\*^](#t2fn0001){ref-type="fn"}--- 372------0.03[^\*^](#t2fn0001){ref-type="fn"}--- 134Poland, 20139.1---0.32---0--18 y63,17335Romania, 2014------0.200.520--5 y1,29037Sweden, 201481---------0--5 y60438Slovakia, 20157410300.30---0--5 y10,35639Spain, 201565000.17---0--5 y9,60240[^19]

Prolongation of hospital stay when RV contagion occurs in hospitalized children is very hard to define. Extra-day of hospitalization was reported only in 12/23 papers selected for this review, shown in [Table 3](#t0003){ref-type="table"}. A median 4.7 d (range 1.7--10) more than normal hospital stay has been calculated for nRV. However, the estimates are deeply different because of the extremely high divergences related to: unclear methodological tools to define extra-days hospitalization for nRV, and the lack of precise and specified referral disease to compare the nRV hospitalization. Once again, Zlamy[@cit0020] compared the estimation of hospitalization in pre- and post-vaccine era with an increased prolongation of hospital stay for post-vaccine era, although it did not reach the statistical significance mainly due to the small sample size for nRV cases (n = 4) in the post-vaccine period ([Table 3](#t0003){ref-type="table"}). Table 3.Extra-days length of hospitalization. nRV hospitalization (mean days ± SD)Extra Length of stay (days)nRV (Sample)Sample size (tot)Age rangeRefGleizes et al.---1.7---5.9[^a^](#t3fn0001){ref-type="fn"}---70---5,470[^a^](#t3fn0001){ref-type="fn"}\<18 y21Stefkovicova M et al.7.323.4[^b^](#t3fn0002){ref-type="fn"}621,635\<5 y23Forster et al.---3.01173,734\<5 y24Festini et al.8.1 ± 5.41.728608\<30 m30Gutiérrez-Gimeno et al.7.5 ± 3.71.7691,5761---23 m31García-Basteiro et al.9.7 ± 13.66[^b^](#t3fn0002){ref-type="fn"}892355,339\<5 y32Panatto et al.---4.4 (SD: ±2.7)2220,690\<5 y33Nitsch-Osuch et al.11.6 ± 0.47[^b^](#t3fn0002){ref-type="fn"}57563,173\<18 y35Zlamy et al.8.04.2[^b^](#t3fn0002){ref-type="fn"}106652,557[^c^](#t3fn0003){ref-type="fn"}\<18 y20 13.310[^b^](#t3fn0002){ref-type="fn"}4305,393[^d^](#t3fn0004){ref-type="fn"}  Konstantopoulos et al.---5 (range: 4---7)822,963\<5 y36Anca et al.---5 (range: 1---10)13753,445\<5 y37Redondo-Gonzalez et al.95[^b^](#t3fn0002){ref-type="fn"}499,602\<18 y40[^20][^21][^22][^23]

Besides a wide variety of incidence rates, we found a high variability of data in particular for nRV definition and epidemiological figures; this variability was formally named as "divergence." The selected papers presented a high level of divergences related to 3 study features (i.e. nRV definition, incidence and extra-days rate), as shown in [Fig. 1](#f0001){ref-type="fig"}. The most important was the information divergence reported for all the selected papers; in particular, 16/23 showed divergence for incidence rate, 15/23 for extra-day evaluation, and 4/23 for nRV definition. Interestingly, information divergences have been observed also for nRV definition in the 4 selected reviews. However, the most important divergences (15/23 studies) related to nRV definition was about selection of cases. Indeed, selection divergences accounted only for nRV definition. Participation divergence was observed in 6/23 paper for both incidence and extra-day evaluation; and finally, surveillance divergence in 5/23 and 8/23 paper for incidence and extra-day estimate respectively. Figure 1.Divergences of 23 selected studies.

Discussion {#s0003}
==========

RV is currently the most common cause of severe AGE in children \<5 yrs worldwide. RV infection is an important public health issue in developed countries for the highest burden on health care resources.[@cit0013] The importance of nRV and the potential of vaccination in its prevention has been highlighted in recent years. RV is generally introduced in the pediatric wards after the hospitalization of children with CARV, especially after their stay in the emergency room before admission. Symptoms of CARV and nRV are similar, with the viral excretion beginning shortly before the clinical starting and persisting up to 57 d after the resolution of diarrhea. The period of transmissibility is around 2 weeks, although it could be longer in immunosuppressed patients. Asymptomatic infection represents 18--39% of all nRV cases with a prevalence in neonates and children \<3 months of age. However, some conditions have been associated with an increased risk of nRV infection: hospitalization length, with an increasing nRV rate after the 6^th^ day; young age; insufficient organization in pediatric services; low hygiene procedures or use of non-disposable tools; high presence of non-medical population (e.g. parents and relatives) in the ward; prematurity and low birth weight; severe immunodeficiency; malnutrition; presence of disease that could prolong hospitalization.[@cit0021]

The introduction of anti-RV vaccine has deeply modified the burden of RV disease, both in the community and in the hospital. The anti-RV vaccination led to an important reduction in terms of ED visit and hospitalization rates in US as much as in Europe. Indeed, many authors evidenced in US an estimate of 11.26/10,000 ED visits and 16.67/10,000 hospitalizations due to CARV in pre-vaccine era,[@cit0042] with an overall hospitalization rate ranging 13--18/10,000 children \<5 yrs.[@cit0042] A hospitalization and ED visits decline is observed in all US regions, with a range around 62--78% for hospitalization and a mean reduction of 57% for ED visits.[@cit0041] These data are similar to results reported by Zlamy[@cit0020] and Giaquinto[@cit0019] in Europe.

In particular, the diffusion of virus in pediatric care settings is difficult to control, as it is repeatedly introduced in the ward from the community. However, nRV phenomenon is often underrated, as most of the studies focused their attention on CARV. Inadequate methodological tool, short duration of studies and small sample size are the most important limitations for nRV evaluation.[@cit0029] In our review, studies on nRV present several issues related to a high rate of methodological divergences.

A good nRV estimation is not possible to achieve, caused by the high heterogeneity of several studies as reported by a recent metanalysis.[@cit0034] A unique definition of nRV was not pointed out, due to the lack of a consensus about international definition of nosocomial infection, as some authors did not recognize that these infections could also appear 48--72 hours after hospital discharge. For this reason, we propose to include the post-discharge onset into nRV definition that could lead to a better methodological evaluation. Moreover, screening of pediatric population admitted to hospital is important to identify some asymptomatic CARV often misdiagnosed with nRV.

Besides the not unique nRV definition, we highlight an important divergence in evaluation of nRV incidence and prolongation of hospital stay. In particular, incidence rates shown in [Table 2](#t0002){ref-type="table"} were mainly characterized by 4 different ways to assess the denominator. Among these indicators, we suggest that only nRV/Hospitalization and nRV/1000 hospitalization-days improve the nRV phenomenon characterization: the former is important to evaluate the nosocomial infection independently from primary diagnosis of hospitalization; the latter could produce an estimation of risk of nRV related to length of hospital stay.

In addition, studies on prolongation of hospital stay for nRV present an extremely wide variety in displaying results. We think that the best way to present the data is to use central tendency measures about extra-days and to correlate them with the mean pediatric hospitalization stay.

The wide difference in results evidenced in our analysis has important socio-economic implications. Indeed, the absence of precise and comprehensive results could hamper a good evaluation of the economic impact of the disease, often referred only to direct costs of hospitalization.[@cit0015] Moreover, we supposed that the lack of indirect cost evaluation is also influenced by the absence of adequate post-discharge follow-up of children with nRV.

Our study has some limitations. Firstly, we did not evaluate the different RV serotypes and the presence of specific strains related to nosocomial infection, even if some authors consider the presence of RV variants (e.g., nursery strains) to explain asymptomatic or mild nRV cases.[@cit0046] The presence of these variants could give an important contribution to the spread of the virus considering the 20--40% asymptomatic children. Another limitation of our study has been not to assess the different healthcare organization among European countries for management of children with acute diarrhea. Indeed, the lack of a consensus for treatment of CARV was reported by Forster, who highlighted a difference in access to participating hospital and ED visits.[@cit0024] Specifically, clearly defined guidelines for CARV treatment as well as the presence of cultural factors could influence health-seeking behaviors. This condition increases the extreme geographical differences of RV infection already reported by PROTECT study.[@cit0011]

RV related disease is an important healthcare issue, especially in case of nosocomial infection where a prolongation of hospital stay has been observed. A good methodological approach is important to enhance the knowledge of nRV in European countries, where there is still no homogeneity in prevention, management and treatment of RV diseases. Planning a cost-effectiveness evaluation on the introduction of anti-RV vaccine to fight the most important cause of dehydrating diarrhea in children \<5 y requires reducing the heterogeneity of studies about nRV.

Methods {#s0004}
=======

An update of the last 10 y for RV epidemiology was made on Pubmed search-engine with following key words: "Rotavirus," "Rotavirus Epidemiology," "Community Acquired Rotavirus Infection," "Rotavirus Hospitalization," "Nosocomial Rotavirus Infection" and "Rotavirus vaccine."

From 8,683 papers counted from 2006 up to September 2015 and filtered for human species, we selected 30 papers. Inclusion criteria for our analysis were original articles (prospective and retrospective studies) about hospitalized CARV or nRV or both with a clear evaluation of: hospitalization rate, hospitalization length, extra-day in hospital stay, incidence and prevalence in developed European countries. Reviews or metanalyses have been included if authors had explored the epidemiology of RV infection requiring hospitalization. Articles with sample aged \>18 years or specific risk category for RV infection, papers related only to genomic or serological typing, and papers exploring only environmental or individual risk factors have been excluded. Finally, we analyzed 10/30 papers concerning hospitalized CARV, and 23/30 about nRV, all related to RV epidemiology before and/or after introduction of anti-RV vaccination.

Furthermore, a systematic evaluation of divergences was made considering 3 features: definition of nRV disease, incidence rate calculation of nRV, and extra-days length for hospital stay in cases of nRV. Each feature was analyzed under 4 different aspects of divergences, based on bias definition:[@cit0047] selection of cases, based on different definition of nRV;information of data, evidenced in different way to calculate rates and summarize data;participation of selected patients, related to a sub-selection of specific patients;surveillance methods, due to the presence or the absence of adequate follow-up.
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